Oxford Nanopore Technologies (LSE:ONT) has obtained a preliminary injunction against MGI Tech GmbH from the Munich Local Division of the Unified Patent Court, restricting the manufacture and sale of MGI’s CycloneSEQ sequencing systems and associated flow cells across several European markets.
The court found sufficient grounds at the preliminary stage to support Oxford Nanopore’s claims that the Cyclone Sequencing Systems infringe two of its European patents.
The injunction covers Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland and the United Kingdom, with limited restrictions also applying in Ireland.
The order is immediately enforceable and includes penalty payments for non-compliance. It restricts MGI Tech’s ability to manufacture or sell the affected sequencing platforms and related flow cells in the specified jurisdictions.
The ruling is preliminary and does not represent a final determination of the underlying patent infringement claims.
Oxford Nanopore intends to seek a permanent injunction through further legal proceedings, with a trial scheduled for October 2027.
The company said the action forms part of its efforts to protect its intellectual property portfolio, which underpins its sequencing technology and commercial operations.
Oxford Nanopore develops nanopore-based molecular sensing technology used for real-time DNA and RNA analysis. Its sequencing platforms are deployed in more than 125 countries across healthcare, scientific research, food and agriculture, and environmental applications.
The company’s technology supports research into cancer, infectious diseases and other biological systems.
The preliminary injunction will remain a significant element of the dispute as Oxford Nanopore pursues a permanent order, with the substantive patent claims scheduled for consideration at the October 2027 trial.
Leave a Reply